Navigation Links
Tunitas Therapeutics Awarded Phase II SBIR Grant to Advance Asthma Program
Date:6/4/2013

SAN FRANCISCO, June 4, 2013 /PRNewswire/ -- Tunitas Therapeutics, Inc., a private company discovering and developing novel human fusion proteins for the treatment of asthma and other allergic diseases, has been awarded a Small Business Innovation Research (SBIR) Phase II grant from the National Institute of Allergy and Infectious Disease (NIAID). The three-year, $3 million grant is aimed at advancing Tunitas' first clinical candidate, a member of the GE2 family, into preclinical development. Specifically the grant will support non-human primate efficacy studies, mechanism of action experiments, and discovery of a next-generation molecule. This grant brings Tunitas' NIH-led grant funding to nearly $10 million.

"This SBIR grant is an important step forward in the development of the Tunitas allergy platform," said Nolan Sigal , President and Chief Executive Officer of Tunitas. "Starting with the ground-breaking work of Dr. Andrew Saxon , Tunitas' co-founder and Emeritus Professor at the UCLA-Geffen School of Medicine, we have successfully advanced the GE2 Program to the point where we expect to begin human clinical trials in 2014."

Tunitas' lead compound GE2 is a fusion protein whose dual mechanism of action positions it to be a game-changing therapeutic for patients with moderate-to-severe asthma uncontrolled by conventional bronchodilators and inhaled corticosteroids, as well as for patients with severe, life-threatening food allergy. GE2 is a direct inhibitor of basophil and mast cell function, the primary cellular mediators of allergic disease, and it suppresses the production of allergic antibodies through its interaction with IgE-producing lymphocytes. GE2 is designed for long-term subcutaneous therapy to be given on an ongoing basis.

Asthma remains a significant unmet medical need in the United States and throughout the world. In the United States alone, this disease every year consumes $18 billion annually in healthcare costs, and, each day, causes 40,000 people to miss school or work, results in 1000 hospital admissions, and causes 11 deaths. Nearly 5 million asthma sufferers are under age 18. Asthma is the most common chronic childhood disease, affecting more than one child in 20.

About Tunitas Therapeutics
Tunitas Therapeutics, Inc. (San Francisco) is a privately held biopharmaceutical company that is developing novel and precisely targeted protein therapeutics with the potential to dramatically change the lives of allergy sufferers.  The company's therapeutic approach offers the potential for long-lasting treatments with safer, faster efficacy than conventional therapies, since they are capable of altering the natural course of such allergic diseases as food allergies, rhinitis and asthma. With close to $10 million raised to date in non-dilutive financing through peer-reviewed grants, Tunitas has successfully executed its capital efficient, semi-virtual business model. For more information on Tunitas Therapeutics, please visit the company's website at www.tunitastherapeutics.com.

Contact:

Nolan H. Sigal , M.D., Ph.D.
President & CEO
Tunitas Therapeutics, Inc.
(650) 887-4747
nsigal@tunitastherapeutics.com

Joan Kureczka
Kureczka/Martin Associates
(415) 821 2413
Joan@kureczka-martin.com


'/>"/>
SOURCE Tunitas Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prime Therapeutics appoints Scott Fries as senior vice president of government programs
2. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
5. Protagonist Therapeutics Names David Liu Chief Scientific Officer
6. Echo Therapeutics to Present at the Jefferies Global Healthcare Conference
7. Alzheimer Market: Drugs, Therapeutics & Diagnostics Research Reports
8. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
9. Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
10. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
11. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis Awareness ... two patients who tell their personal story and encourage those at risk to get tested ... Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... , May 3, 2016 Intec ... a clinical-stage biopharmaceutical company, today announced the appointment of ... Regulatory Affairs. "Ms. Strauss-Levy has 15 years ... has established an outstanding track record, having supported the ... regulatory approval processes in the United States ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information noted ... Medical Records) market in a recent white paper.  The ... Increased physician usage, a growing market are among the ... in Kalorama,s report EMR 2016: The Market ... Kalorama,s seventh complete study of the EMR industry, and ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Pharmacy Times , ... it was chosen as the Pharmaceutical News Provider of the Year in the ... the hard work and dedication of community members who strive to make the ...
(Date:5/4/2016)... ... May 04, 2016 , ... Bayco Products ... tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and NSR-9844XL . , ... starting at $59.95) uses 2 included CR-123 batteries to produce up to 650 ...
(Date:5/4/2016)... ... May 04, 2016 , ... AudioEducator is the ... In upcoming months, AudioEducator has lined up some informative training session for the ... give complete compliance know-how and practical, easy-to-apply advice. , On Thursday, May 19, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Warren L. Smith M.D. , There is ... have plagued people since the beginning of recorded medical history, and in spite ... year. It's not just a matter of inconvenience; bladder infections cost us billions of ...
(Date:5/4/2016)... ... May 04, 2016 , ... Mediware Information Systems, ... software application that helps blood and marrow transplant (BMT) programs meet compliance and ... Mediware has continued to enhance core application features. These enhancements are designed to ...
Breaking Medicine News(10 mins):